Quarterly report pursuant to Section 13 or 15(d)

Equity - Additional Information (Details)

v3.21.2
Equity - Additional Information (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Jul. 27, 2021
USD ($)
May 24, 2021
shares
May 23, 2021
Mar. 28, 2021
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Mar. 31, 2021
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
shares
Mar. 31, 2020
USD ($)
shares
Sep. 30, 2021
USD ($)
D
$ / shares
shares
Sep. 30, 2020
USD ($)
shares
Dec. 31, 2020
$ / shares
shares
Jul. 23, 2021
shares
Stockholders Equity [Line Items]                          
Common stock, shares authorized         500,000,000         500,000,000   500,000,000  
Common stock, par value | $ / shares         $ 0.001         $ 0.001   $ 0.001  
Merger and PIPE Financing shares - common stock         511,065                
Issuance of common stock for exercise of warrants and Unit Purchase Options | $         $ 9,199,471         $ 16,699,489      
Contingently issuable Earnout Shares Excluded from EPS computation         185,472                
Common stock issued for consulting services (in shares)         634,045         834,045      
Non-cash consulting expense | $         $ 7,925,511         $ 12,775,511      
Common stock issued | $         1,134,816 $ 1,562,272 $ 6,927,086 $ 1,412,067 $ 177,025        
Proceeds from issuance of common stock | $                   9,623,899 $ 1,589,103    
Loss on conversion of convertible notes payable | $                     $ 306,641    
Common stock issued to settle note conversion (in shares)                     1,138,199    
Awarded to employees as bonus for services provided             210,800            
Compensation expenses | $         $ 1,559,825     190,750   6,214,853 $ 373,018    
Loss on settlement of accounts payable | $                   $ (120,810)      
Preferred stock, shares authorized         50,000,000         50,000,000   50,000,000  
Preferred stock, shares issued         0         0   0  
Preferred stock, par value | $ / shares         $ 0.001         $ 0.001   $ 0.001  
Number of shares outstanding         0         0   0  
Warrant issued         2,863,637 3,586,250 3,329,812            
Warrant, exercise price per share | $ / shares         $ 9.09 $ 6.63 $ 1.78     $ 9.09   $ 1.09  
Proceeds from exercise of warrant | $ $ 9,186,316                 $ 16,699,489      
Number of shares issued upon exercise of warrants | $             $ 7,500,018            
Net impact to additional paid-in capital | $             $ 60,851,779            
Number of outstanding warrants         9,305,790 8,495,316 4,909,066     9,305,790   3,075,470  
Change in fair value of the warrants | $                   $ (1,208,412)      
Number of units outstanding         600,000         600,000     600,000
Price per unit | $ / shares         $ 10.00         $ 10.00      
Aggregate exercise price | $         $ 6,000,000         $ 6,000,000      
Number of shares per unit                   1      
Number of shares per right                   1      
Unit expiration term                   5 years      
Demand right term                   5 years      
Piggy back right term                   7 years      
Fractional shares issued upon conversion of rights                   0      
Unamortized compensation costs | $         $ 32,644,383         $ 32,644,383      
Substitute Warrants                          
Stockholders Equity [Line Items]                          
Warrant, exercise price per share | $ / shares         $ 2.45         $ 2.45      
Warrants exercised         4,909,066         4,909,066      
Deemed dividend - Earnout Shares | $                   $ 2,691,799      
Net impact to additional paid-in capital | $                   0      
Incremental compensation on modification | $                   2,330,572      
Unamortized compensation costs | $         $ 23,760,993         23,760,993      
Additional deemed dividend recognized in the event of earnout shares milestone | $                   24,379,657      
Additional deemed dividend recognized in the event of earnout cash milestone | $                   $ 3,068,732      
Public Warrants                          
Stockholders Equity [Line Items]                          
Warrant, exercise price per share | $ / shares         $ 11.50         $ 11.50      
Warrants exercised         1,144         1,144      
Gross proceeds from exercise of warrants | $         $ 13,156                
Number of outstanding warrants         3,450,000         3,450,000      
Number of shares per warrant         1         1      
Warrants expiration term         5 years         5 years      
Redemption price per warrant (in dollars per share) | $ / shares                   $ 0.01      
Minimum threshold written notice period for redemption of warrants                   30 days      
Stock price trigger for redemption of warrants (in dollars per share) | $ / shares                   $ 21.00      
Threshold trading days for redemption of warrants | D                   20      
Redemption period | D                   30      
Number of warrants per unit                   1      
Placement Warrants                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants         136,250         136,250      
Change in fair value of the warrants | $         $ (260,238)     0   $ 1,208,412 0    
Public Right                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants         6,900,000         6,900,000      
Number of shares per unit                   1      
Number of shares per right                   1      
Placement Rights                          
Stockholders Equity [Line Items]                          
Number of outstanding warrants         272,500         272,500      
Merger agreement                          
Stockholders Equity [Line Items]                          
Merger and PIPE Financing shares - common stock                   3,729,730      
Merger agreement | Stockholders of NeuroRx                          
Stockholders Equity [Line Items]                          
Exchange Ratio   3.16 4.96                    
Common stock warrants | Legacy NeuroRx Warrants                          
Stockholders Equity [Line Items]                          
Warrant issued       3,329,812                  
Warrant, exercise price per share | $ / shares       $ 3.19                  
Warrant expiry date       Mar. 27, 2024                  
Fair value on the date of issuance | $       $ 60,851,779                  
Warrants exercised       1,496,216                  
Gross proceeds from exercise of warrants | $       $ 7,500,018                  
Proceeds from exercise of warrant | $ 1,833,596                        
Number of shares issued upon exercise of warrants | $ $ 9,186,316                        
General and administrative                          
Stockholders Equity [Line Items]                          
Compensation expenses | $         $ 1,340,023     $ 64,604   $ 5,778,606 $ 182,073    
Common Stock                          
Stockholders Equity [Line Items]                          
Merger and PIPE Financing shares - common stock         3,238,338     292,534   3,642,515 343,378    
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)         2,334,370         3,830,586      
Proceeds from issuance of common stock | $         $ 31,134,816     $ 1,412,067   $ 39,624,175 $ 1,589,092    
Awarded to employees as bonus for services provided               200,000   200,000      
Common Stock | General and administrative                          
Stockholders Equity [Line Items]                          
Compensation expenses | $                   $ 4,850,000      
Legacy NeuroRx Preferred Stock | Convertible Series A Preferred Stock                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized         1,000,000         1,000,000   1,000,000  
Preferred stock, shares issued         1,000,000         1,000,000   1,000,000  
Preferred stock, par value | $ / shares         $ 0.001         $ 0.001   $ 0.001  
Preferred stock, conversion basis                   one share of common stock for each preferred share      
Convertible preferred stock, liquidation preference per share | $ / shares         $ 1.00         $ 1.00   $ 1.00  
Number of shares outstanding   2,367,543                      
Shares issued upon conversion   7,480,836                      
Legacy NeuroRx Preferred Stock | Convertible Series B-1 Preferred Stock                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized         1,050,695         1,050,695   1,050,695  
Preferred stock, shares issued         1,050,695         1,050,695   1,050,695  
Convertible preferred stock, liquidation preference per share | $ / shares         $ 7.58         $ 7.58   $ 7.58  
Legacy NeuroRx Preferred Stock | Convertible Series B-1A Preferred Stock                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized         316,848         316,848   316,848  
Preferred stock, shares issued         316,848         316,848   316,848  
Convertible preferred stock, liquidation preference per share | $ / shares         $ 6.82         $ 6.82   $ 6.82  
Legacy NeuroRx Preferred Stock | Convertible Series B-2 Preferred Stock                          
Stockholders Equity [Line Items]                          
Preferred stock, shares authorized                       100,000  
Preferred stock, shares issued                 4,167        
Preferred stock, par value | $ / shares                       $ 0.001  
Preferred stock, conversion basis                       one share of common stock for each share of B-2 Preferred Stock  
Convertible preferred stock, liquidation preference per share | $ / shares                       $ 12.00  
Number of shares outstanding   4,167                      
Shares issued upon conversion   13,168